Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01509547 · ClinicalTrials.gov registry record · Phase 3
Varenicline for Adolescent Smoking Cessation
A Phase 3 study, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- Phase 3
- Development phase
- 157
- Enrollment target
NCT01509547 is a Phase 3 study that has completed, run by Medical University of South Carolina. The registered enrollment target is 157 participants.
The verdict
NCT01509547, a Phase 3 study, has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 157 participants
- Enrollment target
Study Summary
This is a placebo-controlled smoking cessation treatment study for adolescents ages 14-21. After assessment and inclusion into the study, participants will be randomized to receive a 12-week double blind course of varenicline or placebo.
Interventions
- DRUG placebo
- DRUG Varenicline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 157 participants |
| Start Date | 2012-08 |
| Est. Completion | 2018-01-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01509547
The ClinicalTrials.gov registry entry for NCT01509547 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 157 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which placebo is the first listed.
NCT01509547 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01509547 about?
NCT01509547 is a clinical study titled "Varenicline for Adolescent Smoking Cessation". This is a placebo-controlled smoking cessation treatment study for adolescents ages 14-21. After assessment and inclusion into the study, participants will be randomized to receive a 12-week double blind course of varenicline or placebo.
What is the current status of trial NCT01509547?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 157 participants. The study started on 2012-08. Estimated completion is 2018-01-26.
What interventions are being tested in trial NCT01509547?
The interventions under investigation include: placebo (DRUG), Varenicline (DRUG).
Who is sponsoring clinical trial NCT01509547?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.